Background: DMR is a minimally invasive, endoscopic procedure designed to treat insulin resistance-related metabolic diseases via hydrothermal rejuvenation of duodenal mucosa leading to improvement in insulin sensitivity. Primary (24 week) results from REVITA-2, the first randomized, sham-controlled, double-blind, prospective, multicenter study, demonstrated that a single DMR procedure safely elicits significant improvements in glycemic and hepatic parameters in sub-optimally controlled T2D. Here we report on durability of glycemic results through 48 weeks posttreatment in REVITA-2 patients at 9 European study centers.

Method: Eligible patients were aged 28-75 years, taking ≥ 1 OAD, had HbA1c levels 7.5%-10.0%, and BMI of 24-40 kg/m2. The modified intent-to-treat (mITT) population included randomized patients in whom a procedure was attempted. Patients lost to follow up were excluded, and data obtained post-rescue medication were set to missing. Significance (0.05 level) was determined using a 2-sided Wilcoxon signed-rank test.

Results: Thirty-one of 39 patients randomized to DMR (mITT) were followed to 48 weeks. Median change from baseline HbA1c was -0.6% at 24 weeks (n = 38, p = 0.003) and -0.7% at 48 weeks (n = 27, p < 0.001). Sixty-eight percent of patients achieved a reduction in HbA1c from baseline at 24 weeks (median HbA1c change: -1.1%) and were defined as responders. Most responders (84%) maintained a durable response through 48 weeks (median HbA1c change: -1.0%) without an increase in antidiabetic medication. Median weight change was -2.4 kg at 24 weeks (n = 38, p < 0.001) and -2.1 kg at 48 weeks (n = 28, p = 0.003).

Conclusion: A single DMR procedure safely elicits durable, clinically significant glycemic improvements through 48 weeks posttreatment in suboptimally controlled T2D; most patients who respond at 24 weeks maintain the beneficial effects at 48 weeks without needing additional medication.

Disclosure

G. Mingrone: Consultant; Self; Fractyl Laboratories, Inc., Johnson & Johnson, Novo Nordisk A/S. D. Hopkins: Advisory Panel; Self; Fractyl Laboratories, Inc., Roche Diabetes Care. Speaker’s Bureau; Self; AstraZeneca, Novo Nordisk A/S, Sanofi, Sunovion Pharmaceuticals Inc. G. Aithal: None. G. Costamagna: Advisory Panel; Self; Cook Medical, Ethicon, Inc., Olympus. Research Support; Self; Apollo EndoSurgery, Boston Scientific. L. Crenier: Advisory Panel; Self; AstraZeneca, Boehringer Ingelheim International GmbH, Eli Lilly and Company, Novo Nordisk Inc., Sanofi. J.M. Deviere: Research Support; Self; Fractyl Laboratories, Inc. R. Drummond: None. R. Haidry: None. I.R. I: None. A. Lania: Research Support; Self; Ipsen Biopharmaceuticals, Pfizer Inc. C. Magee: None. M. Nieuwdorp: Board Member; Self; Caelus Health, Kaleido Biosciences. V. Bhambhani: None. J. Huang: Employee; Self; Fractyl Laboratories, Inc. K. White: Employee; Self; Fractyl Laboratories, Inc. Stock/Shareholder; Self; Johnson & Johnson. J. Lopez-Talavera: Employee; Self; Fractyl Laboratories, Inc. H. Rajagopalan: Employee; Self; Fractyl Laboratories, Inc. J.J. Bergman: Research Support; Self; Fractyl Laboratories, Inc. Other Relationship; Self; Fractyl Laboratories, Inc.

© 2020 by the American Diabetes Association
2020
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.